Matveychuk, Dmitriy
MacKenzie, Erin M.
Kumpula, David
Song, Mee-Sook
Holt, Andrew
Kar, Satyabrata
Todd, Kathryn G.
Wood, Paul L.
Baker, Glen B. http://orcid.org/0000-0003-1581-6486
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-86712)
Article History
Received: 29 December 2020
Accepted: 10 March 2021
First Online: 10 April 2021
Declarations
:
: GBB has had informal discussions about phenelzine with NeuraWell Therapeutics, but the company has had no input into this manuscript. EMM now works for Lundbeck Canada, but the company has had no input into this manuscript. The authors have no other conflicts of interest to declare.